Immunogenicity evaluation of RBD subunit vaccine formulated with CpG 1826 adjuvant
10.3760/cma.j.cn112866-20241017-00152
- VernacularTitle:CpG 1826佐剂配伍的RBD亚单位疫苗的免疫原性评价
- Author:
Yuhan YAN
1
;
Shengli BI
1
;
Yao YI
1
;
Qiudong SU
1
Author Information
1. 中国疾病预防控制中心病毒病预防控制所，北京 102206
- Publication Type:Journal Article
- Keywords:
Severe acute respiratory syndrome coronavirus 2;
Receptor-binding domain;
Subunit vaccine;
CpG 1826;
Immunogenicity
- From:
Chinese Journal of Experimental and Clinical Virology
2024;38(6):681-686
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate immunogenicity of receptor binding domain (RBD) subunit vaccine formulated with CpG 1826 adjuvant in mice.Methods:BALB/c mice were intramuscularly inoculated with two doses of RBD recombinant protein formulated with CpG 1826 adjuvant. The level of the specific IgG antibodies and neutralizing antibodies (NAbs) in serum were detected by ELISA and microneutralization assay, respectively. The effector T lymphocytes secreting IFN-γ and IL-4 in mice spleen were quantified by ELISpot.Results:RBD protein formulated with CpG 1826 adjuvant induced a high level of specific IgG antibodies (18 820.27) and NAbs, which had cross-neutralizing activity against SARS-CoV-2 prototype (776), BA.2 (676), and XBB.1.5 (97) variants. The specific effector T lymphocytes secreting IFN-γ and IL-4 in mice spleen were 382.4±16.1 and 180.6±4.78, respectively. Combined with an IgG1/IgG2a ratio (0.88) in serum, RBD protein formulated with CpG 1826 adjuvant induced Th1-type predominant immune response in mice.Conclusions:RBD subunit vaccine formulated with CpG 1826 adjuvant induced the strong cellular and humoral immune responses in mice, providing a scientific basis for the adjuvant application of SARS-CoV-2 subunit vaccines.
